Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma - PubMed (original) (raw)
doi: 10.1111/jpi.12032. Epub 2013 Jan 17.
Affiliations
- PMID: 23330677
- DOI: 10.1111/jpi.12032
Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma
Karolina Jablonska et al. J Pineal Res. 2013 Apr.
Abstract
In humans, two main types of membrane melatonin receptors have been identified, MT1 and MT2. Expression of MT1 in neoplastic cells seems to increase the efficacy of melatonin's oncostatic activity. The purpose of this study was to determine the distribution and the intensity of MT1 expression in breast cancer cells and to correlate it with clinicopathological factors. Immunohistochemical studies (IHC) were conducted on 190 cases of invasive ductal breast carcinomas (IDC) and molecular studies were performed on 29 cases of frozen tumor fragments and selected breast cancer cell lines. Most of the studied tumors manifested a membranous/cytoplasmic IHC expression of MT1. In IDC, the MT1 expression was higher than in fibrocystic breast disease. MT1 expression was higher in estrogen receptor positive (ER+) and HER2 positive (HER2+) tumors. Triple negative tumors (TN) manifested the lowest MT1 expression level. The lowest MT1 protein expression level was noted in the TN breast cancer cell line MDA-MB-231 compared with ER+ cell lines MCF-7 and SK-BR-3. MT1 mRNA expression was negatively correlated with the malignancy grade of the studied IDC cases. Moreover, higher MT1 expression was associated with patients' longer overall survival (OS) in the group of ER+ breast cancers and treated with tamoxifen. Multivariate analysis indicated that MT1 was an independent prognostic factor in the ER+ tumors for OS and event-free survival in the ER+ tumors. The results of this study may point to a potential prognostic and therapeutic significance of MT1 in IDC.
© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.
Similar articles
- Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma.
Hartog H, Horlings HM, van der Vegt B, Kreike B, Ajouaou A, van de Vijver MJ, Marike Boezen H, de Bock GH, van der Graaf WT, Wesseling J. Hartog H, et al. Breast Cancer Res Treat. 2011 Oct;129(3):725-36. doi: 10.1007/s10549-010-1256-6. Epub 2010 Nov 24. Breast Cancer Res Treat. 2011. PMID: 21107683 - Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines.
Treeck O, Haldar C, Ortmann O. Treeck O, et al. Oncol Rep. 2006 Jan;15(1):231-5. Oncol Rep. 2006. PMID: 16328061 - Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T, Tsuda H, Moriya T, Yamasaki T, Kikuchi R, Ueda S, Omata J, Yamamoto J, Matsubara O. Kobayashi T, et al. Breast Cancer Res Treat. 2010 Oct;123(3):733-45. doi: 10.1007/s10549-009-0672-y. Epub 2009 Dec 18. Breast Cancer Res Treat. 2010. PMID: 20020198 - Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines.
Lai L, Yuan L, Cheng Q, Dong C, Mao L, Hill SM. Lai L, et al. Breast Cancer Res Treat. 2009 Nov;118(2):293-305. doi: 10.1007/s10549-008-0220-1. Epub 2008 Nov 4. Breast Cancer Res Treat. 2009. PMID: 18979234 - Melatonin: A Potential Therapeutic Option for Breast Cancer.
Kong X, Gao R, Wang Z, Wang X, Fang Y, Gao J, Reiter RJ, Wang J. Kong X, et al. Trends Endocrinol Metab. 2020 Nov;31(11):859-871. doi: 10.1016/j.tem.2020.08.001. Epub 2020 Sep 3. Trends Endocrinol Metab. 2020. PMID: 32893084 Review.
Cited by
- pH-Responsive Fluorescence Enhanced Nanogel for Targeted Delivery of AUR and CDDP Against Breast Cancer.
Cao Z, Li W, Liu R, Li C, Song Y, Liu G, Chen Y, Lu C, Lu A, Liu Y. Cao Z, et al. Int J Nanomedicine. 2020 Oct 29;15:8369-8382. doi: 10.2147/IJN.S274842. eCollection 2020. Int J Nanomedicine. 2020. PMID: 33149581 Free PMC article. - Effect of Melatonin on Chemoresistance Exhibited by Spheres Derived from Canine Mammary Carcinoma Cells.
Cataldo D, Aravena G, Escobar A, Tapia JC, Peralta OA, Torres CG. Cataldo D, et al. Animals (Basel). 2024 Apr 19;14(8):1229. doi: 10.3390/ani14081229. Animals (Basel). 2024. PMID: 38672378 Free PMC article. - From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review.
Valdivia G, Alonso-Diez Á, Pérez-Alenza D, Peña L. Valdivia G, et al. Front Vet Sci. 2021 Feb 17;8:623800. doi: 10.3389/fvets.2021.623800. eCollection 2021. Front Vet Sci. 2021. PMID: 33681329 Free PMC article. Review. - Membrane Melatonin Receptors Activated Cell Signaling in Physiology and Disease.
Nikolaev G, Robeva R, Konakchieva R. Nikolaev G, et al. Int J Mol Sci. 2021 Dec 31;23(1):471. doi: 10.3390/ijms23010471. Int J Mol Sci. 2021. PMID: 35008896 Free PMC article. Review. - Expression of the MT1 melatonin receptor in ovarian cancer cells.
Jablonska K, Pula B, Zemla A, Kobierzycki C, Kedzia W, Nowak-Markwitz E, Spaczynski M, Zabel M, Podhorska-Okolow M, Dziegiel P. Jablonska K, et al. Int J Mol Sci. 2014 Dec 12;15(12):23074-89. doi: 10.3390/ijms151223074. Int J Mol Sci. 2014. PMID: 25514412 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous